Cellular immune response following homologous and heterologous BNT162b2 booster vaccination after primary immunization with BNT162b2 and CoronaVac respectively

Mat Jusoh Siti Asmaa

doi:10.1016/j.cellimm.2026.105064

Cellular immune response following homologous and heterologous BNT162b2 booster vaccination after primary immunization with BNT162b2 and CoronaVac respectively

2026-01-31

0

PRE

AI

M

Mat Jusoh Siti Asmaa

D

Darren Shaqeel Sasikaran

A

Aini Syahida Mat Yassim

B

Bushra Solehah Mohd Rosdan

A

Amiratul Aifa Mohamad Asri

A

Anis Atifah Mohd Hisham

R

Rapeah Suppian

N

Nur Suhaila Idris

R

Rosediani Muhamad

M

Maryam Azlan *

M

Mohd Nor Norazmi *

DOI：10.1016/j.cellimm.2026.105064

Original

Original request for help

Save

Abstract

En 中文

• Sustained T cell activation at T2 (6–8 months post-booster) in both PPP and SSP groups, as evidenced by increased CD25 + CD69+ and CD38 + HLA-DR+ expression on CD4+ and CD8+ T cells. • Distinct kinetics of memory T cells, with the SSP group exhibiting prolonged Central and Stem Cell Memory T cell responses at T3 (12 months post-booster) compared to PPP. • Higher IL-2, TNF-α, and IFN-γ cytokine responses in the SSP group, suggesting a stronger cellular immune response. • A decline in T cell markers at 12 months, emphasizing the potential need for additional booster doses to maintain protection against emerging SARS-CoV-2 variants.

Cellular immune response following homologous and heterologous BNT162b2 booster vaccination after primary immunization with BNT162b2 and CoronaVac respectively

Abstract

Journal

Organization

Cited Papers

Citing Papers